NEW YORK, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced the appointment of Briggs W. Morrison, M.D. to the Company’s Advisory Board. Dr. Morrison brings extensive experience leading companies in drug development, having served as Chief Medical Officer of AstraZeneca and Head of Clinical Development for Pfizer. Briggs is currently Chief Executive Officer of Syndax Pharmaceuticals Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.
“Briggs has an incredible depth of development expertise and his perspective will be invaluable as we advance SM-88 and other programs through clinical development,” said Steve Hoffman, CEO of Tyme. “As we strive to assemble an outstanding team, Briggs will be complementary in both expertise and character.”
“Tyme’s platform is a truly differentiated way to treat cancer and I am excited to help with the development of what could be a paradigm shifting therapy,” said Briggs. “It has also been a pleasure to work with Steve and understand his innovative thinking around pharmaceutical development.”
Dr. Morrison’s career includes distinguished roles with AstraZeneca, Pfizer, and Merck & Co., Inc. As Chief Medical Officer and Executive Vice President of Global Medicine Development at AstraZeneca, Briggs oversaw all clinical development projects. As Head of Clinical Development with Pfizer, he oversaw Phase I-III development and operations for all therapeutic areas before being appointed Head of Development, Medical Affairs, Safety and Regulatory Affairs for all of Pfizer’s Human Health businesses. While serving as Head of Oncology Development at Merck, Briggs oversaw the development and approval of vorinostat (Zolinza) for treatment of cutaneous T-cell lymphoma.
Briggs has also served as Chairman of the Board of TransCelerate BioPharma, an industry-funded company charged with improving aspects of clinical trials. Briggs received his BS (Biology) from Georgetown University and his MD from the University of Connecticut. Briggs trained in Internal Medicine at the Massachusetts General Hospital and in Medical Oncology at the Dana-Farber Cancer Institute.
Tyme Technologies, Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, our therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. Our lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and we are preparing to initiate an additional Phase II clinical trial for pancreatic cancer. For more information, visit our website: www.tymeinc.com.